British Association of Dermatologists Guidelines for Biologic Therapy for Psoriasis 2017

C.H. Smith; Z.K. Jabbar-Lopez; Z.Z. Yiu; T. Bale; A.D. Burden; L.C. Coates; M. Cruickshank; T. Hadoke; E. MacMahon; R. Murphy; C. Nelson-Piercy; C.M. Owen; R. Parslew; E. Peleva; E. Pottinger; E.J. Samarasekera; J. Stoddart; C. Strudwicke; V. A. Venning; R.B. Warren; L.S. Exton; M.F. Mohd Mustapa


The British Journal of Dermatology. 2017;177(3):628-636. 

In This Article

Stakeholder Involvement and Peer Review

The full version of the guideline was made available to the BAD membership, British Society for Paediatric Dermatology, British Dermatological Nursing Group, Primary Care Dermatological Society, British Society for Paediatric and Adolescent Rheumatology, British Society of Rheumatology, Royal College of Obstetrics and Gynaecology, Psoriasis and Psoriatic Arthritis Alliance, Psoriasis Association and relevant pharmaceutical companies (see Appendix G in File S2 in Supporting Information for the full list of stakeholders), comments from whom were actively considered by the guideline development group. Following further review, the finalized version was peer reviewed by the Clinical Standards Unit of the BAD, made up of the Therapy & Guidelines subcommittee, prior to submission for publication.